Latest Innovation News

Sea Forest Limited launches a $20.5 million IPO on the ASX to scale production and commercialisation of SeaFeed™, a scientifically validated livestock feed additive that cuts methane emissions by up to 80% while boosting productivity.

Alfabs Australia Limited reported robust financial gains in FY2025, including a maiden dividend and major contract completion, while signaling cautious optimism for 2026 amid softer markets and uncertain project pipelines.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chrysos Corporation reported record FY25 financial results, driven by strong global demand for its innovative PhotonAssay™ technology. The company expanded its footprint, enhanced sustainability credentials, and strengthened governance, positioning itself for continued growth.

Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

OpenLearning has secured a landmark three-year SaaS and referral agreement with Field Ready, a leading African education-to-employment provider, marking a significant expansion into emerging markets with its AI-powered LMS.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

Integrated Research Limited reported a modest revenue dip and significant profit declines in FY25 as it pivots to a product-led growth strategy focused on AI-powered observability solutions and hybrid pricing models.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.